Celltrion: 투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 유럽 임상 3상 시험계획 변경신청 승인(Part1&2))
AI reading
★★★ Bullish · Material event
Darzalex biosimilar EU Phase 3 clinical trial approval
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
Other filings by Celltrion
- 09.23 ★★★ Zymfentra US Phase 3 clinical trial approval (rheumatoid arthritis)
- 09.23 ★★ Large Shareholding Report (General)
- 09.16 ★★ Cancellation of treasury shares for stock price stabilization and shareholder value enhancement
- 09.07 ★★★ Keytruda biosimilar US Phase 3 clinical trial amendment approval
- 09.07 ★★★ Darzalex biosimilar Korea Phase 3 clinical trial amendment approval
- 08.31 ★★★★ Plan for share buyback and full cancellation to stabilize stock price and enhance shareholder value
For information only. Not investment advice.